In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and ...

CHICAGO, March 30 (Reuters) - The highest dose of an experimental drug developed by Eli Lilly (LLY.N), opens new tab significantly reduced levels of a genetically inherited risk factor for heart ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...